Comparative Pharmacology
Head-to-head clinical analysis: ARBLI versus CEFTAZIDIME IN DEXTROSE CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARBLI versus CEFTAZIDIME IN DEXTROSE CONTAINER.
ARBLI vs CEFTAZIDIME IN DEXTROSE CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
10 mg orally once daily.
1-2 g intravenously every 8 hours.
None Documented
None Documented
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic